mk-7762
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 23, 2023 (NCT05824091)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Mycobacterium tuberculosisINHIBITOR
Mycobacterium tuberculosis inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07094932 | Phase 1 | Sep 3, 2025 | Bill and Melinda Gates Foundation |
| NCT05824091 | Phase 1 | Feb 23, 2023 | Bill and Melinda Gates Foundation, Merck |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bill and Melinda Gates Foundation | Academic/Hospital | 2 | 2 | 1 | 2023 |
| Merck | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1